Onco-Innovations' Inka Health Enhances Global Medical Data Use

Onco-Innovations Limited's subsidiary, Inka Health Corp, has published a significant technical primer in the Journal of Clinical Evaluative Research. This publication tackles the complexities of using real-world evidence (RWE) across borders, a key issue in healthcare decision-making. Co-authored with AstraZeneca Canada, it presents advanced statistical methods to adapt medical evidence for international use, which may expedite regulatory approvals and patient access to innovative therapies, especially in rare disease contexts.

The primer introduces three fundamental principles—consistency, positivity, and conditional exchangeability—for the dependable sharing of cross-border evidence. It outlines various statistical techniques like matching and weighting, crucial for adapting non-local RWE, and highlights their integration into Inka Health's SynoGraph platform, enhancing global healthcare decisions.

The document puts emphasis on rare diseases, where limited local data hinders drug approvals, offering solutions to this impediment. The incorporation of these methods into SynoGraph aims at overcoming global data hurdles, fostering precise and swift treatment decisions worldwide.